Company intelligence / Profile preview

Tolmar

Fort Collins, Colorado, USAtolmar.com ↗
Ownership
Private
Development stage
Other
01

Overview

Tolmar’s lead product ELIGARD® (leuprolide acetate for injectable suspension) uses the proprietary Atrigel delivery system and is approved for advanced prostate cancer. The company also manufactures and develops other long-acting injectable therapies in endocrinology and urology. Clinical results have established ELIGARD as an effective LHRH agonist for testosterone suppression in prostate cancer patients; it has been commercialized globally with ongoing collaborations to expand access.

Therapeutic areas
OncologyEndocrinology
Modalities
Long-acting injectablesSynthetic peptides (e.g., leuprolide acetate)Small molecules
Industry
Biotech
02

Drug pipeline

5 assets

TOL-2506

Approved

4 more assets in the full pipeline.

03

Partnerships

Sanofi Canada – collaboration on Eligard commercialization in CanadaAstellas Pharma – previous agreement for Eligard rights outside North America; rights returned to Tolmar in some regions recently.

Beyond the preview

Go deeper on Tolmar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tolmar.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call